To better understand the relative attractiveness of the IPO market, and how their venture backers have done so far, I thought it would be illustrative to look at the biotech IPOs that have made it public since early July in greater depth: Durata, Hyperion, Regulus, Kythera, and Intercept.
FORBES: Biotech IPOs Are Back! Maybe.